Charles T. Gombar, Ph.D., BS ’74

Untitled Document
Charles Gombar
“The science community at Pace was very small, and it was more like a family. Although I was a Chemistry major, it was a Biology professor, Dr. Cyrus Bacchi, who first told me about a field called Pharmacology. Five or so years later, I completed my Ph.D. in Pharmacology and was on my way.”

Charles T. Gombar, Ph.D., BS ’74
Senior Vice President, Project Management and Pharmaceutical Development
Endo Pharmaceuticals

 

Senior Vice President, Project Management and Pharmaceutical Development
Endo Pharmaceuticals

Dr. Gombar is currently Senior Vice President of Project Management and Pharmaceutical Development at Endo Pharmaceuticals. He leads a group of project leaders and project managers responsible for the successful development of new drugs and devices, a group of scientists responsible for formulation development. In addition, Dr. Gombar is responsible for overall portfolio management for Endo R&D.

Prior to joining Endo in May of 2010, Dr. Gombar was head of the Development Strategy and Operations Optimization within Biotherapeutics Research at Pfizer (formerly Wyeth). He joined Wyeth Research in 1997 where he held several positions.

Prior to the acquisition of Wyeth by Pfizer he was VP, R&D Strategy and Business Improvement.  In that role he lead a group whose purpose was to help define the strategic path forward in R&D to help Wyeth thrive in the increasingly challenging environment and to drive process improvements in R&D. Prior to that Dr. Gombar led the team developing methylnaltrexone for treatment of opioid-induced constipation and post-operative ileus.  The methylnaltrexone team was Wyeth Research’s first “High-Impact” development team.  Before the methylnaltrexone assignment Dr. Gombar was VP, Project Management, responsible for all R&D projects in Neuroscience and Women’s Health & Bone, as well as drug development training for all project team members. While at Wyeth he served as project leader for the development of zaleplon (Sonataâ), new indications for the antidepressant venlafaxine (Effexor XRâ), and other agents being developed for Alzheimer’s disease, schizophrenia, neuropathic pain, and stroke.

In 2005 Dr. Gombar co-lead the Wyeth Research portion of the corporate-wide “Springboard” project. The goal of Springboard was to prepare Wyeth for the future, and the goal of the R&D portion of Springboard was to design the “Clinical Development Paradigm of the Future”. The key outcome of the R&D Springboard project was the implementation of the “Learn & Confirm” paradigm for pharmaceutical product development.

Prior to joining Wyeth, Dr. Gombar held positions in the Drug Metabolism Department as well as Project Management at SmithKline Beecham, where he was project leader for several cardiovascular development projects including carvedilol (Coreg®). He spent several years in Project management at Sterling Winthrop where his project responsibilities included the antiplatelet agent clopidogrel (Plavix®).  Dr. Gombar’s other Project Management experience was at Knoll Pharmaceutical Co. where he led development efforts in Neuroscience. Dr. Gombar also served a Vice President of Clinical Operations at the CRO Biopharm Clinical Services.

Dr. Gombar was active in various Project Management organizations such as the Project Management subsection in PMA (now PhRma) and was the first chairperson of the Project Management Special Interest Advisory Group in the Drug Information Association. He has been involved in development and teaching courses for the Pharmaceutical Education Research Institute since 1997. He is also serving in the curriculum committee and teaching faculty for the American Course in drug Development and Regulatory Science being sponsored by the University of California, San Francisco.

Dr. Gombar received his undergraduate degree in Chemistry from Pace University and his Ph.D. in Pharmacology from the Albany Medical College.